TYRA · Tyra Biosciences, Inc. · Metrics
$20.55
-0.05 (-0.24%)
At close · Oct 22
Return incl. dividend (before tax)
Market Cap
$1.24B
Shares
59.68M
Volume · Oct 21
724.35K
Avg daily vol (3M)
859.02K
TYRA metrics
68 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$20.60
Market cap
$1.24B
Price action
20 metricsPrice change (1W)
+10.2%
Price change (30D)
-19.4%
Price change (3M)
-32.7%
Price change (6M)
-44.8%
Price change (YTD)
-21.6%
Price change (1Y)
+40.0%
Trailing year
Price change (5Y)
-4.1%
52-week high
$39.61
52-week low
$13.99
Change from 52-week high
-48.0%
Change from 52-week low
+47.2%
Annualized volatility
67.8%
Annualized volatility (3M)
83.9%
Beta
0.5
RSI (14D)
46.0
Price vs SMA 50
-11.7%
Price vs SMA 200
-31.7%
Avg volume (3M)
859,015
Relative volume
0.8
Average dollar volume
$20.91M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
59.68M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.5
reciprocal yield 28.6%
FCF yield
-8.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-09-09
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$160.46M
Net income (TTM)
−$148.56M
Trailing 12 months
Diluted EPS (TTM)
$-2.40
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+10.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-42.0%
Return on assets
-38.8%
Debt / equity
0.0
Current ratio
14.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$109.90M
Quick ratio
14.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$73.83M
Latest balance sheet
Cash & equivalents
$73.83M
Total assets
$383.36M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$109.65M
Capital expenditures (TTM)
$250,000
R&D (TTM)
$126.32M
SG&A (TTM)
—
Stock compensation (TTM)
$33.28M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
170
13F filer change QoQ
+6
Institutional ownership
117.0%
Conviction holders (share of 13F filers)
4.2%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.0%
Holder tenure
11.6
Price vs estimated holder cost
+24.4%
Ownership (registered funds)
1 metricsIndex-fund ownership
10.4%
Short interest
3 metricsShort interest
15.8%
Latest settlement · 8.8 days to cover
Days to cover
8.8d
Short-squeeze score
74 / 100
Insider activity
2 metricsNet insider buying (90D)
$19,982
Insider-sentiment score
74 / 100
Risk flags
1 metricsGoing concern
—